Clinical Trial Update: Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rosuvastatin to reduce cardiovascular risk in HIV-infected individuals has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• HIV Infection

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: HIV Infections, Heart Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-03-08